Revvity (NYSE:RVTY) Stock Rating Lowered by Weiss Ratings

Revvity (NYSE:RVTY) was downgraded by Weiss Ratings from a “hold (c-)” rating to a “sell (d+)” rating in a note issued to investors on Wednesday,Weiss Ratings reports.

Several other research firms have also commented on RVTY. Barclays cut their target price on shares of Revvity from $110.00 to $100.00 and set an “overweight” rating for the company in a research note on Thursday, October 2nd. Wall Street Zen downgraded shares of Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 3rd. Stifel Nicolaus reduced their price target on shares of Revvity from $120.00 to $110.00 and set a “hold” rating for the company in a research report on Tuesday, July 29th. Raymond James Financial restated an “outperform” rating and issued a $115.00 price target (down previously from $120.00) on shares of Revvity in a research report on Tuesday, July 29th. Finally, Evercore ISI reduced their price target on shares of Revvity from $108.00 to $106.00 and set an “outperform” rating for the company in a research report on Tuesday. Ten investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Revvity presently has a consensus rating of “Moderate Buy” and a consensus price target of $117.93.

Revvity Trading Up 0.8%

Shares of NYSE:RVTY opened at $91.90 on Wednesday. Revvity has a twelve month low of $81.36 and a twelve month high of $129.50. The firm has a market cap of $10.67 billion, a P/E ratio of 38.94, a P/E/G ratio of 3.04 and a beta of 0.98. The company has a 50 day moving average of $88.00 and a 200-day moving average of $93.18. The company has a current ratio of 3.33, a quick ratio of 2.75 and a debt-to-equity ratio of 0.43.

Revvity (NYSE:RVTY) last released its earnings results on Monday, July 28th. The company reported $1.18 EPS for the quarter, beating the consensus estimate of $1.14 by $0.04. Revvity had a net margin of 10.19% and a return on equity of 7.66%. The business had revenue of $720.28 million during the quarter, compared to analyst estimates of $711.26 million. During the same period in the prior year, the business earned $1.22 earnings per share. The business’s quarterly revenue was up 4.1% on a year-over-year basis. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. As a group, analysts anticipate that Revvity will post 4.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC increased its stake in shares of Revvity by 20.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,952 shares of the company’s stock worth $553,000 after purchasing an additional 838 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of Revvity by 21.2% during the 1st quarter. Farther Finance Advisors LLC now owns 796 shares of the company’s stock worth $83,000 after purchasing an additional 139 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Revvity by 42.9% during the 1st quarter. GAMMA Investing LLC now owns 2,713 shares of the company’s stock worth $287,000 after purchasing an additional 815 shares during the last quarter. Pullen Investment Management LLC acquired a new position in shares of Revvity during the 1st quarter worth $377,000. Finally, Ritholtz Wealth Management acquired a new position in shares of Revvity during the 1st quarter worth $210,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.